Minimum Requirements for Reporting Clinical Trials Evaluating the Therapeutic Potential of Platelet-Rich Plasma
August 2020
in “
Journal of The American Academy of Dermatology
”
New to Platelet-Rich Plasma? There is a guide in the encyclopedia. Read the guide → 
Studysummary This letter comments on a randomized controlled trial by Shapiro et al that found no significant benefits of platelet-rich plasma compared to placebo for male androgenetic alopecia, highlighting issues with PRP protocol variations.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The document outlined the minimum requirements for reporting clinical trials evaluating the therapeutic potential of platelet-rich plasma (PRP). Key elements included initial blood volume, anticoagulant type, centrifugation parameters, PRP preparation and application methods, and detailed characterization of PRP components such as platelet size, red and white blood cell counts, and growth factor levels. Specifics for PRP application in treating androgenetic alopecia (AGA) were provided, including intradermal administration on the scalp with a dosage of 0.1-0.2 ml per injection/cm², administered in three doses at one-month intervals. The guidelines aimed to standardize reporting to improve the reproducibility and comparability of PRP clinical trials.
